Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Problems in the structure of clinical trials

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 21.05.12
Views: 3750

Prof Thomas Tursz – Institut Gustave Roussy, Paris, France

Prof Thomas Tursz talks to ecancer about the movement towards personalised medicine and the current problems in clinical trials in Berlin, May 2012.


The movement towards personalised medicine indicates a need for reorganisation in clinical trials. In clinical trials, 97% of patients in Europe are not in a trial. These patients are at a disadvantage because the process of joining a clinical trial involves a much more thorough analysis of their disease. Data shows that patients in clinical trials have better outcomes than those not in them.

Related videos

follow us

Core Surgical Training

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation